Activation-induced cytidine deaminase (AID) is essential for somatic hypermutation of B-cells. We investigated the expression of AID mRNA by real-time polymerase chain reaction (PCR) in peripheral blood mononuclear cells of 80 patients with B-CLL. AID expression was detected in 45 of 80 patients (56%) at various levels, but was undetectable in 35 patients (44%). AID PCR positivity was associated with unmutated IGV H gene status (22 of 25 patients; P ¼ 0.002) and unfavourable cytogenetics (18 of 23 patients with deletion in 11q or loss of p53; P ¼ 0.040). Using a threshold level of 0.01-fold expression compared to Ramos control cells, even more significant associations were observed (P ¼ 0.001 for IGV H ; P ¼ 0.002 for cytogenetics). A correlation was observed between individual AID levels and the percentage of V H homology (R ¼ 0.41; P ¼ 0.001). AID positivity predicted unmutated IGV H status with an odds ratio of 8.31 (P ¼ 0.003) and poor risk cytogenetics with an odds ratio of 3.46 (P ¼ 0.032). Significance was retained after adjustment for Binet or Rai stages. AID mRNA levels were stable over time. These data suggest a potential role of AID as a prognostic marker in B-CLL.
Introduction
The prognosis of patients with chronic lymphocytic leukaemia (B-CLL) is generally determined by the clinical staging systems of Binet and Rai, which are based on the degree of bone marrow insufficiency, lymphadenopathy and organomegaly. [1] [2] [3] [4] Unfortunately, theses systems are unable to predict disease progression in early stages (Binet A, Rai 0-II) or resistance to chemotherapy. Subsequently, novel prognostic factors have been defined: lymphocyte doubling time (LDT), pattern of bone marrow infiltration, LDH, serum b2-microglobulin, soluble CD23, serum thymidine kinase, expression of CD38, cytogenetic aberrations and mutational status of immunoglobulin heavy chain variable region genes (IGV H ). [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Of these, cytogenetics and IGV H mutational status are currently the best predictors of outcome, independent of clinical stage. [13] [14] [15] However, their use is restricted to specialized laboratories and therefore a small number of patients. In search for surrogate markers, mRNA and protein expression of the 70 kDa T-cell receptor z-chainassociated protein tyrosine kinase (ZAP-70) has been shown to correlate with IGV H mutational status. [20] [21] [22] [23] [24] Activation-induced cytidine deaminase (AID) is normally expressed in CD19 þ /CD38 þ germinal centre B-cells and essential for somatic hypermutation, suggesting its potential association with IGV H mutational status. [25] [26] [27] [28] [29] Indeed, two reports have recently described the expression of AID in unmutated B-CLL cases. 28, 30 However, a third study found no association between AID expression and IGV H mutation status. 31 Here we report the establishment of a Ramos-calibrated realtime PCR assay for AID mRNA expression in peripheral blood cells. In a series of 80 patients, we found a strong association of AID expression with unmutated IGV H genes, unfavourable cytogenetic aberrations (deletion in 11q, loss of p53, trisomy 12), and a less-pronounced association with LDT, LDH or CD38 protein expression. The data suggest that AID expression could serve as a novel prognostic factor in B-CLL.
Patients and methods
A total of 80 B-CLL patients (51 male, 29 female, median age 64 years) seen at the Division of Hematology, University of Vienna in various Binet stages (55 Binet A, 11 Binet B, 14 Binet C) were included in the present study after informed consent was obtained. All patients had a sustained lymphocytosis (more than 5 Â 10 9 l) and a CD19 þ /CD5 þ /CD23 þ B-cell clone. The percentage of lymphocytes in the differential blood count ranged from 37 to 93%. The majority of patients (n ¼ 59) were untreated at the time of blood collection. After a median observation time of 37 months, only three patients have died.
Information about the levels of LDH and b2-microglobulin was available in all patients, surface CD38 (measured by flow cytometry, FACScant, Becton Dickinson, San Jose, CA, USA) was determined in 78 patients, serum levels of soluble CD23 were available in 52 patients. LDT could be evaluated in 59 cases. In all, 30 patients were enrolled in clinical trials (CLL1, CLL2H, CLL3, CLL4) of the German CLL Study Group (GCLLSG).
Determination of IGV H mutational status
IGV H mutational status was determined at the University of Ulm in 57 patients, as previously described. 15 In brief, genomic DNA from cryopreserved PB mononuclear cells was prepared according to standard procedures. PCR amplification of the clonal VDJ rearrangement was performed with fluorochromelabelled 5 0 -V H FRI family-specific primers together with a 3 0 -J H FRIV primer mix for the identification of the rearranged V H family using genescan analyses. After purification, the PCR products were directly sequenced with the appropriate nonlabelled 5 0 -V H primers on a genetic analyzer model 377 (Applied Biosystems, Foster City, CA, USA) using dye terminator chemistry (Big Dye Kit; Applied Biosystems). In all cases, at least one independent PCR product was sequenced for verification. The VDJ nucleotide sequences were aligned to current databases (EMBL/GenBank, V-base directory). Homology to the nearest germline gene was calculated in relation to the sequenced fragment.
Fluorescence-in situ hybridisation
Relevant genetic aberrations were assessed by fluorescence-in situ hybridisation (FISH) at the Department of Medical Biology, University of Vienna, in 74 patients, as described. 9 FISH on interphase nuclei from peripheral blood cells after cultivation for 24 h was performed using a panel of CLL-specific probes (probes 13S272 (Qbiogene, Carlsbad, CA, USA) and LSI 13/RB-1 DNA (Vysis, Downers Grove, IL, USA) for 13q14, LSI p53 (Spectrum Orange;Vysis) for 17p13.1, LSI IGH Dual Color Breakapart Probe (Vysis) for 14q32, D11Z1 (Oncor, Gaithersburg, MD, USA) for centromere 11 and YAC 755_b_11 for 11q22-q23, D12Z3 (Oncor) for centromere 12 and YAC 754_a_1 for 12q13); 250-500 nuclei were examined for each probe or probe combination.
In 53 patients, both cytogenetic as well as IGV H gene analysis were performed.
Real-time PCR
RNA and cDNA were prepared from unsorted frozen peripheral blood (PB) mononuclear cells using RNA-Beet (Tel-Test Inc., Friendswood, TX, USA) and first-strand cDNA Synthesis kit (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA).
Real-time PCR was performed with the ABI Prism 7000 Sequence Detector (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. To control for sample quality, 11 housekeeping genes were first tested in eight CLL samples. Expression profile of the endogenous control genes showed low variation of DCt values for b-actin (VICt labelled pre-developed TaqMan s Assay reagent, Applied Biosystems), which was subsequently used as endogenous control. PCR was carried out in a 25 ml reaction volume using 1 ml of a 1:10 cDNA dilution with AID-specific primers (designed from sequences in exons 1 and 2, Assays-on-Demand Gene Expression system, Applied Biosystems), probes and TaqMan s Universal Master Mix without AmpErase s UNG. The primers in this assay amplify the wild-type AID and several splice variants. 30 All samples were run in duplicates. The AID expression levels given in this study represent the mean value of these two independent measurements. Real-time PCR negativity was defined by the absence of amplified product after 40 cycles. In four patients, one negative and one positive result was obtained. In these cases, a second duplicate analysis was performed, which showed two negative results. These cases were scored PCR-negative.
Messenger RNA of the Burkitt's lymphoma cell line Ramos was used as a calibrator for relative quantification. In addition to 80 peripheral blood samples of CLL patients, quantification of AID was performed in normal peripheral blood, spleen, CD3 sorted T-cells and kidney. The RNA of kidney and spleen was obtained from BD Biosciences Clontech (Palo Alto, CA, USA).
Peripheral blood of CLL patients was collected for AID mRNA analysis at two different time points (range: 3-24 months) in eight CLL patients.
Statistical analysis
Binary data are compared between two groups using Fisher's exact test. Due to the exploratory character of the tests, no correction for multiplicity has been performed. Association between AID on the one hand and cytogenetic risk groups and mutational status, respectively, on the other hand is described by Spearman correlation coefficients. Confidence intervals (95%) for these coefficients are computed via bootstrapgenerated quantiles, after transforming the Spearman correlations (from 999 simulation runs) by the inverse tanh-function for variance stabilization. 32 The potency of AID to predict cytogenetic risk and dichotomised mutational status, respectively, was assessed using logistic regression and described by crude and adjusted odds ratios and their respective 95% confidence intervals, where adjustment refers to Binet or Rai stages, respectively.
P-values p0.05 were considered to be statistically significant. Fisher's exact tests, correlations, bootstrap simulations and logistic regression were performed using SAS Version 8.2 (SAS Institute Inc., Cary, NC, USA, 2001).
Results

Expression of AID mRNA in B-CLL and controls measured by real-time PCR
The highest expression of AID was found in the mutating Burkitt's lymphoma cell line Ramos. Using Ramos as a calibrator, 0.001-fold expression was measured in human spleen, while very low (mean 0.0004; range 0.00004-0.0009) levels were detected in PB mononuclear cells from three healthy volunteers. CD3-sorted peripheral T-cells and kidney tested negative (not shown).
Variable levels of AID (range 0.00005 to 0.38) were detected in 45 out of 80 patients (56%) (Figure 1 , patients #1-45). In all, 35 patients (44%) showed no detectable expression of AID in PB mononuclear cells (patients #46-80). For subsequent statistical analysis, AID negativity was defined by the absence of AID expression in duplicate analysis. 
AID expression and IGV H mutational status
Out of 57 patients, 25 (44%) tested had unmutated IGV H genes (defined by more than 98% homology to the best matching V H ). Of these 25 unmutated patients, 22 (88%) expressed AID mRNA in our real-time PCR assay. In the group of mutated patients (N ¼ 32), AID could be detected in only 15 cases (47%) ( Table 1) . Out of 20 AID-negative patients, 17 had mutated IGV H genes with less than 98% homology. In univariate analysis, AID PCR positivity was significantly associated with unmutated IGV H gene status (P ¼ 0.002) ( Table 1, lanes 2-4) . The distribution of individual AID levels in mutated and unmutated cases is shown in Figure 2a . Interestingly, this association became even stronger when a cutoff of 96% V H homology was used (Po0.001) (Figure 2b ).
In addition, we found a significant positive correlation between individual AID levels and the percentage of V H homology (range 86.6-100%) (R ¼ 0.41; P ¼ 0.001, CI 0. 15 Discordant AID expression: Three of 25 unmutated cases were AID-negative (patients #49, 52 and 59; Table 2 ). Two patients had LDTs of 12 months or less but a CD38 expression of less than 30%. The other patient had a high CD 38. Of the 15 mutated AID-positive cases, five had more than 96% V Hhomology. We identified two mutated patients with very high AID levels (40.01). Both had trisomy 12 (Table 2) . Interestingly, the patient with the highest AID level (0.38, patient #1; Table 2 ; Figure 2a ) used a mutated V H 3-21 gene. This feature has been linked to poor prognosis, similar to that of unmutated patients. 18 
AID expression and cytogenetic aberrations
Cytogenetic abnormalities specific to CLL were observed by FISH in 60 of 74 samples tested (81%). Of these, 31 had one abnormality, 20 had two abnormalities and nine patients had more than two abnormalities. There were 14 patients with normal karyotype, 20 with deletion in 13q as the sole abnormality, 18 with abnormalities of chromosome bands 14q32, 12 with trisomy 12, 13 with deletions in 11q and 11 with loss of p53. The distribution of AID-positive and AIDnegative cases among these groups is shown in Table 1 . Interestingly, 10 of 13 patients with a deletion in 11q were PCRpositive for AID. When the known poor risk factor deletions in 11q or loss of p53 were combined, the relationship was even more pronounced (18/23; P ¼ 0.040). A significant correlation of individual AID expression levels with this high-risk group was found (R ¼ 0.37; P ¼ 0.001, CI 0.10, 0.56). The odds ratio of an AID-expressing patient to have unfavourable cytogenetics (deletion in 11q or loss of p53) was 3.46 (CI 1.12, 10.75; P ¼ 0.032) and remained unchanged after adjustment for Binet and Rai stages.
Seven patients had simultaneous deletions in 11q and 13q. These patients had median AID levels ( ¼ 0.003) comparable to those of deletion in 11q ( ¼ 0.003) but not 13q ( ¼ 0.0001).
Within the 53 patients, in whom V H gene mutational status, cytogenetics and AID expression were known, associations were observed which are in line with previous observations: 14,15 eight of 13 cases with deletion in 11q were unmutated and 10 of 13 were AID-positive, six of nine cases with loss of p53 were unmutated and eight of nine were AID-positive; on the other hand, 11 of 14 cases with deletion in 13q as the sole abnormality were mutated, but only four of them were AID negative.
Definition of a different threshold level
We then compared the individual expression values of the poor risk (deletion in 11q, loss of p53; N ¼ 23) and good risk (deletion in 13q as sole abnormality, normal karyotype; N ¼ 34) cytogenetic groups (Figure 3) . The median value of expression was considerably higher in the poor risk group (0.003, range 0-0.296 vs 0.00007, range 0-0.27). Interestingly, all but two of the good risk cases expressed AID less than 0.01-fold relative to Ramos. Using this threshold level for statistical considerations led to a more pronounced association between AID, IGV H mutational status or cytogenetics (Table 1, lanes 5-7) . AID expression of more than 0.01-fold was now associated with deletions in 11q with a P-value of 0.008. For the group of patients with deletions in 11q or loss of p53, the significance increased to P ¼ 0.002. A significant association was now observed with trisomy 12 (P ¼ 0.005). Association of AID with unmutated V H gene status, LDH and CD38 was also enhanced.
Association of AID expression with other prognostic factors
The association of AID expression with other prognostic factors is shown in Table 1 . There was no significant association with Clinical outcome: Out of 80 patients, 21 had already received various first-line chemotherapeutic regimens, predominantly chlorambucil or nucleoside analogues before blood was taken for AID evaluation. Another two patients were treated after their first blood collection. Of these, eight had undetectable AID expression and 15 were AID-positive. Responses to first-line therapy were observed in the AID-negative group (three partial remissions) as well as in the AID-positive group (one complete remission, three partial remissions). Since only three patients have died so far, no evaluations regarding survival can be made.
Stability of AID mRNA during the course of disease
Peripheral blood was collected at two different time points (interval 3-24 months) in eight patients. As shown in Table 3 , seven patients remained within the positive or negative groups, respectively. Only patient #80 moved from the negative to the positive group with low AID expression (0.0007-fold). In patient #36 AID expression remained unchanged after chemotherapy, despite a considerable drop in leukocyte counts. These data suggest that AID mRNA is a stable molecular target.
Discussion
This study establishes the role of AID as a predictor of IGV H mutational status with an odds ratio of 8.31. AID negativity was associated with mutated IGV H genes in 17 of 20 cases. On the other hand, 22 of 25 unmutated cases were AID positive using the generally accepted cutoff of 98% V H homology. Interestingly, if the cutoff was set at 96%, 27 of 29 'unmutated' cases showed AID expression. This finding is in line with similar observations for clinical outcome. 15 Since the data were generated by real-time PCR, more detailed expression levels could be analysed. The individual quantitative AID levels were also significantly correlated with the percentage of V H homology. The median level of AID was much lower in mutated B-CLL. However, discordant AID expression was observed. Three of 25 unmutated cases were AID negative and 15 mutated cases expressed AID. Within this latter group, five patients had more than 96% V H homology. Interestingly, the one patient with the highest expression used a mutated V H 3-21 gene, similar to the recent observations concerning ZAP-70 expression. 22 Our data support the suggestions regarding the association of AID expression and mutational status made in two pivotal observations. 28, 30 However, the findings are in contrast to the recent report of Albesiano et al. 31 These authors used more cycles for real-time amplification and found that all patients were PCR-positive. This underscores the necessity of standardization and the definition of appropriate threshold levels for AID.
We have attempted to solve this problem by using a cell line as a calibrator and by the definition of discriminatory levels through association with cytogenetic risk groups reported here for the first time.
The most striking finding was the relationship of AID expression with deletions in 11q and loss of p53. These aberrations define a group of patients with poor prognosis or nodal involvement. 9, 10 We compared AID-negative (N ¼ 5) and AID-positive (N ¼ 18) patients within this group of 23 patients. Interestingly, all the four AID-negative patients in whom IGV H status was known were mutated, while 13 of 17 AID-positive patients were unmutated. This suggests biological differences between subgroups.
In addition, the observation that patients with simultaneous deletions in 11q and 13q had relatively high AID levels indicates that these cases are more closely related to 11q deletion, fitting with the hierarchical model of genomic aberrations.
9 Table 3 Stability of AID mRNA expression over time The odds of an AID-expressing patient to have unfavourable cytogenetics remained significant after adjustment for Binet and Rai stages. This indicates a relationship between AID and cytogenetics independent of clinical stage.
Interestingly, we also found a significant association of high AID mRNA expression with trisomy 12, possibly due to the location of the gene on this chromosome. 30 Six of 13 patients with AID levels above 0.01 had trisomy 12.
Only poor correlation was observed with markers of tumor burden like b2-microglobulin or soluble CD23. On the other hand, an association was found with LDH, LDT and CD38. The expression of CD38 on B-CLL cells is also a potential predictor of IGV H -mutational status, but may change over time. 13 At this time, our data do not allow valid statistical analysis in regard to clinical outcome. However, the results obtained here warrant the validation in patients enrolled in clinical trials with known long-term outcome.
The IGV H -mutating cell line Ramos was used as a calibrator. This approach may be useful to establish a standardized Q-PCR assay for AID. As a caveat, AID expression in Ramos may change over time, requiring frequent quality controls. 33 In general, AID levels in CLL were low compared to Ramos and distributed over 4 logs in our population.
Weak expression of AID was observed in PB of normal individuals. This could lead to false-positive results in the small group of patients with comparably low levels and a high percentage of polyclonal B-cells. Unfortunately, this problem can probably not be circumvented by purification of CD19 þ Bcells. 30 In our patients, it seemed that AID-negative CLL cells were so predominant that expression of AID in normal B-cells did not play a role. We interpret this fact as a bias in the ratio between CLL and normal B-cells in patient samples. Thus, AID expression in a very low number of normal B-cells cannot be detected under the conditions used. Our data indicate that determination of AID in PB mononuclear cell fractions is not decisively influenced by leukocyte counts or the percentage of lymphocytes in the differential blood count.
The value of risk factors used for prediction at diagnosis is largely dependent on their stability over time. While AID expression is inducible in vitro by stimulation with various agents, we found only little variation in AID expression in vivo, even after therapy. 31 Using the discrimination between AID-negative and AIDpositive values, significant associations with IGV H mutational status and cytogenetics were observed. However, the best clinically applicable cutoff level has not been determined yet. Increasing the threshold to 0.01 of Ramos allowed the definition of a group of patients with good risk cytogenetics (normal karyotype or deletion in 13q as the sole abnormality) (Figure 3 ). On the other hand, all patients above this threshold had poor risk cytogenetics and/or unmutated IGV H status, or used a V H 3-21.
The following three subgroups regarding IGV H mutational status can be defined: This means that the predictive value is high in the lower and upper extremes, but low in group 2 which still comprises about half of the patients.
The discriminatory power of real-time PCR will help to define better cutoff levels associated with clinical outcome when homogenous patient groups from controlled trials are investigated.
AID is expressed in germinal centre B-cells of CD19 þ / CD38 þ phenotype, and is normally downregulated during maturation. 26, 29 One could speculate that the association of AID with deletion in 11q (frequently observed in nodal CLL) and CD38 expression is somehow related to the pattern of CD19 þ / CD38 þ /IgD À germinal centre cells. 34 The majority of unmutated cases were AID-positive, but even 47% of mutated cases still expressed AID. Constitutive expression of AID in transgenic mice results in T-cell lymphomas with massive point mutations in T-cell receptor genes and oncogenes, and interestingly, occasional gains and losses of chromosomes. 35 It remains to be determined, whether AID expression precedes cytogenetic aberrations or has escaped from downregulation in these cells after maturation arrest.
In summary, AID mRNA expression can easily be determined by real-time PCR. The significant association with IGV H mutational status and specific cytogenetic aberrations independent of clinical stage could establish AID as a new prognostic marker in B-CLL.
